Search details
1.
Loss-of-function mutations in ndh do not confer delamanid, ethionamide, isoniazid, or pretomanid resistance in Mycobacterium tuberculosis.
Antimicrob Agents Chemother
; 68(1): e0109623, 2024 Jan 10.
Article
in English
| MEDLINE | ID: mdl-38038476
2.
Pyrazinamide-resistant Tuberculosis Obscured From Common Targeted Molecular Diagnostics.
Drug Resist Updat
; 68: 100959, 2023 05.
Article
in English
| MEDLINE | ID: mdl-37043916
3.
Population Pharmacokinetics and Dose Evaluation of Cycloserine among Patients with Multidrug-Resistant Tuberculosis under Standardized Treatment Regimens.
Antimicrob Agents Chemother
; 67(5): e0170022, 2023 05 17.
Article
in English
| MEDLINE | ID: mdl-37097151
4.
The ddn Trp20Stop Mutation and Its Association with Lineage 4.5 and Resistance to Delamanid and Pretomanid in Mycobacterium tuberculosis.
Antimicrob Agents Chemother
; 66(12): e0102622, 2022 12 20.
Article
in English
| MEDLINE | ID: mdl-36409105
5.
Distribution of Common and Rare Genetic Markers of Second-Line-Injectable-Drug Resistance in Mycobacterium tuberculosis Revealed by a Genome-Wide Association Study.
Antimicrob Agents Chemother
; 66(6): e0207521, 2022 06 21.
Article
in English
| MEDLINE | ID: mdl-35532237
6.
Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid.
J Antimicrob Chemother
; 77(6): 1685-1693, 2022 05 29.
Article
in English
| MEDLINE | ID: mdl-35260883
7.
Genotypic Resistance of Pyrazinamide but Not Minimum Inhibitory Concentration Is Associated With Longer Time to Sputum Culture Conversion in Patients With Multidrug-resistant Tuberculosis.
Clin Infect Dis
; 73(9): e3511-e3517, 2021 11 02.
Article
in English
| MEDLINE | ID: mdl-33011791
8.
Detection of Pyrazinamide Heteroresistance in Mycobacterium tuberculosis.
Antimicrob Agents Chemother
; 65(9): e0072021, 2021 08 17.
Article
in English
| MEDLINE | ID: mdl-34181476
9.
Atypical Genetic Basis of Pyrazinamide Resistance in Monoresistant Mycobacterium tuberculosis.
Antimicrob Agents Chemother
; 65(6)2021 05 18.
Article
in English
| MEDLINE | ID: mdl-33722890
10.
Systematic Review of Whole-Genome Sequencing Data To Predict Phenotypic Drug Resistance and Susceptibility in Swedish Mycobacterium tuberculosis Isolates, 2016 to 2018.
Antimicrob Agents Chemother
; 64(5)2020 04 21.
Article
in English
| MEDLINE | ID: mdl-32122893
11.
Non-commercial phenotypic assays for the detection of Mycobacterium tuberculosis drug resistance: a systematic review.
Eur J Clin Microbiol Infect Dis
; 39(3): 415-426, 2020 Mar.
Article
in English
| MEDLINE | ID: mdl-31667670
12.
Minimum Inhibitory Concentrations of Fluoroquinolones and Pyrazinamide Susceptibility Correlate to Clinical Improvement in Multidrug-resistant Tuberculosis Patients: A Nationwide Swedish Cohort Study Over 2 Decades.
Clin Infect Dis
; 69(8): 1394-1402, 2019 09 27.
Article
in English
| MEDLINE | ID: mdl-30561569
13.
Detection of Mycobacterium tuberculosis pncA Mutations by the Nipro Genoscholar PZA-TB II Assay Compared to Conventional Sequencing.
Antimicrob Agents Chemother
; 62(1)2018 01.
Article
in English
| MEDLINE | ID: mdl-29084743
14.
Distribution of plasma concentrations of first-line anti-TB drugs and individual MICs: a prospective cohort study in a low endemic setting.
J Antimicrob Chemother
; 73(10): 2838-2845, 2018 10 01.
Article
in English
| MEDLINE | ID: mdl-30124844
15.
Ebselen and analogs as inhibitors of Bacillus anthracis thioredoxin reductase and bactericidal antibacterials targeting Bacillus species, Staphylococcus aureus and Mycobacterium tuberculosis.
Biochim Biophys Acta
; 1860(6): 1265-71, 2016 Jun.
Article
in English
| MEDLINE | ID: mdl-26971857
16.
Non-pncA Gene-Mutated but Pyrazinamide-Resistant Mycobacterium tuberculosis: Why Is That?
J Clin Microbiol
; 55(6): 1920-1927, 2017 06.
Article
in English
| MEDLINE | ID: mdl-28404681
17.
Multicenter Study of the Emergence and Genetic Characteristics of Pyrazinamide-Resistant Tuberculosis in China.
Antimicrob Agents Chemother
; 60(9): 5159-66, 2016 09.
Article
in English
| MEDLINE | ID: mdl-27297481
18.
Determination of MIC Breakpoints for Second-Line Drugs Associated with Clinical Outcomes in Multidrug-Resistant Tuberculosis Treatment in China.
Antimicrob Agents Chemother
; 60(8): 4786-92, 2016 08.
Article
in English
| MEDLINE | ID: mdl-27246779
19.
Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China.
Eur Respir J
; 57(3)2021 03.
Article
in English
| MEDLINE | ID: mdl-33154028
20.
Drug resistance characteristics and cluster analysis of M. tuberculosis in Chinese patients with multiple episodes of anti-tuberculosis treatment.
BMC Infect Dis
; 16: 4, 2016 Jan 07.
Article
in English
| MEDLINE | ID: mdl-26739444